Kevin Price, Senior Vice President Vaccines Business, Avecia Biologics Ltd. commented, "We are confident that the combined capabilities of Avecia and PharmAthene will significantly enhance the overall timeliness and opportunity for success of the development and commercialization programs."
Following completion of the sale and purchase agreement, PharmAthene's
biodefense portfolio will include:
-- a recombinant Protective Antigen (rPA) anthrax vaccine
-- Valortim(TM), a fully human monoclonal antibody being co-developed with
Medarex for the prevention and treatment of anthrax infection
-- Protexia(R) a novel bioscavenger to prevent and treat organophosphate
nerve agent poisoning
-- a new type of plague vaccine based on recombinant technology
manufactured in E coli
-- A third generation rPA anthrax vaccine program
rPA Anthrax Vaccine
In February 2008 the Department of Health and Human Services (DHHS) issued a formal solicitation (Request for Proposals) for an Anthrax Recombinant Protective Antigen (rPA) Vaccine for the Strategic National Stockpile (SNS). The solicitation outlines a requirement to procure 25 million doses of an rPA anthrax vaccine.
Avecia's rPA vaccine, which has completed Phase II clinical testing, is a second generation rPA anthrax vaccine for use against human anthrax infection. The objective of the program is to develop, through FDA approval, an rPA-based anthrax vaccine that can be stored, transported and used without the need for a conventional cold chain -- an important advantage for civilian biodefense deployment under the Strategic National Stockpile.
"There is currently a tremendous unmet need for a s
|SOURCE PharmAthene, Inc.|
Copyright©2008 PR Newswire.
All rights reserved